{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:05:08Z","timestamp":1762520708373,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Royal Dutch Society for Pharmacy"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.conctc.2018.100308","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T12:24:43Z","timestamp":1543407883000},"page":"100308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The effect of a structured medication review on quality of life in Parkinson's disease: The study protocol"],"prefix":"10.1016","volume":"13","author":[{"given":"N.G.M.","family":"Oonk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.L.L.","family":"Movig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.M.","family":"Munster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Koehorst-Ter Huurne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"van der Palen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.D.A.","family":"Dorresteijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.conctc.2018.100308_bib1","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson's disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.conctc.2018.100308_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","article-title":"Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030","volume":"68","author":"Dorsey","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.conctc.2018.100308_bib3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.conctc.2018.100308_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy","volume":"14","author":"Parkinson","year":"2002","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.conctc.2018.100308_bib5","series-title":"Parkinson's Disease: Diagnosis and Treatment","first-page":"99","article-title":"Pathophysiology and clinical assessment of motor symptoms in Parkinson's disease","author":"Jankovic","year":"1987"},{"issue":"1\u20132","key":"10.1016\/j.conctc.2018.100308_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2011.05.006","article-title":"The importance of non-motor disturbances to quality of life in Parkinson's disease","volume":"310","author":"Martinez-Martin","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.conctc.2018.100308_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.conctc.2018.100308_bib8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","article-title":"What contributes to quality of life in patients with Parkinson's disease?","volume":"69","author":"Schrag","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.conctc.2018.100308_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/pds.682","article-title":"Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients","volume":"11","author":"Leoni","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"Suppl 2","key":"10.1016\/j.conctc.2018.100308_bib10","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1007\/s00415-010-5716-z","article-title":"Has drug therapy changed the natural history of Parkinson's disease?","volume":"257","author":"Clarke","year":"2010","journal-title":"J. Neurol."},{"issue":"20","key":"10.1016\/j.conctc.2018.100308_bib11","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the uncidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.conctc.2018.100308_bib12","first-page":"CD006564","article-title":"Dopamine agonist therapy in early Parkinson's disease","author":"Stowe","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.conctc.2018.100308_bib13","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/mds.20609","article-title":"Burden of illness in Parkinson's disease","volume":"20","author":"Huse","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.conctc.2018.100308_bib14","first-page":"A3031","article-title":"Insufficient medication compliance in Parkinson's disease","volume":"155","author":"Aerts","year":"2011","journal-title":"Ned. Tijdschr. Geneeskd."},{"issue":"11","key":"10.1016\/j.conctc.2018.100308_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/mds.20525","article-title":"Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease","volume":"20","author":"Grosset","year":"2005","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.conctc.2018.100308_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/mds.21831","article-title":"Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease","volume":"23","author":"Kulkarni","year":"2008","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.conctc.2018.100308_bib17","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.clinthera.2013.09.001","article-title":"Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson's disease","volume":"35","author":"Wei","year":"2013","journal-title":"Clin. Therapeut."},{"issue":"2","key":"10.1016\/j.conctc.2018.100308_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/0002512-200926020-00006","article-title":"Challenges of treatment adherence in older patients with Parkinson's disease","volume":"26","author":"Bainbridge","year":"2009","journal-title":"Drugs Aging"},{"issue":"29","key":"10.1016\/j.conctc.2018.100308_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-014-0220-0","article-title":"Medication adherence in patients with Parkinson's disease","author":"Malek","year":"2015","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.conctc.2018.100308_bib20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40258-013-0033-1","article-title":"Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis","volume":"11","author":"Richy","year":"2013","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.conctc.2018.100308_bib21","first-page":"CD000011","article-title":"Interventions for enhancing medication adherence","volume":"11","author":"Nieuwlaat","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.conctc.2018.100308_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.conctc.2018.100308_bib23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.amjopharm.2010.08.001","article-title":"Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence","volume":"8","author":"Tarrants","year":"2010","journal-title":"Am. J. Geriatr. Pharmacother."},{"issue":"527","key":"10.1016\/j.conctc.2018.100308_bib24","article-title":"Dosing frequency and medication adherence in chronic disease","volume":"18","author":"Coleman","year":"2012","journal-title":"J. Manag. Care Pharm."},{"issue":"8","key":"10.1016\/j.conctc.2018.100308_bib25","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin. Therapeut."},{"issue":"6","key":"10.1016\/j.conctc.2018.100308_bib26","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mds.22112","article-title":"Adherence to antiparkinson medication in a multicenter European study","volume":"24","author":"Grosset","year":"2009","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.conctc.2018.100308_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.parkreldis.2014.10.021","article-title":"Relationships between antiparkinson medication nonadherence, regimen modifications, and healthcare utilization and expenditures","volume":"21","author":"Wei","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.conctc.2018.100308_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mds.22999","article-title":"Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data","volume":"25","author":"Davis","year":"2010","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.conctc.2018.100308_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.conctc.2018.100308_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcgg.2015.05.001","article-title":"Medication adherence in the elderly","volume":"7","author":"Yap","year":"2016","journal-title":"J. Clin. Gerontol. Geriatr."},{"issue":"10","key":"10.1016\/j.conctc.2018.100308_bib31","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.parkreldis.2012.09.004","article-title":"Systematic review on factors associated with medication non-adherence in Parkinson's disease","volume":"18","author":"Daley","year":"2012","journal-title":"Park. Relat. Disord."},{"issue":"7","key":"10.1016\/j.conctc.2018.100308_bib32","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1468-1331.2010.03320.x","article-title":"Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study","volume":"18","author":"Valldeoriola","year":"2011","journal-title":"Eur. J. Neurol."},{"year":"2013","series-title":"Polyfarmacie Bij Kwetsbare Ouderen: Inventarisatie Van Risico's En Mogelijke Interventiestrategie\u00ebn","author":"Lemmens","key":"10.1016\/j.conctc.2018.100308_bib33"},{"year":"2008","series-title":"A Guide to Medication Review","author":"Clyne","key":"10.1016\/j.conctc.2018.100308_bib34"},{"issue":"2","key":"10.1016\/j.conctc.2018.100308_bib35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11096-018-0602-3","article-title":"Changes in medicine prescription following a medication review in older high-risk patients with polypharmacy","volume":"40","author":"Hurmuz","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.conctc.2018.100308_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamainternmed.2014.5841","article-title":"Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis","volume":"175","author":"Viswanathan","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.conctc.2018.100308_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/pharmacy6020032","article-title":"Improving pharmacists' targeting of patients for medication review and deprescription","volume":"6","author":"Marvin","year":"2018","journal-title":"Pharmacy"},{"issue":"4","key":"10.1016\/j.conctc.2018.100308_bib38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.sapharm.2016.08.005","article-title":"Pharmacist-led medication review in community settings: an overview of systematic reviews","volume":"13","author":"Jokanovic","year":"2017","journal-title":"Res. Soc. Adm. Pharm."},{"issue":"12","key":"10.1016\/j.conctc.2018.100308_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009235","article-title":"Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review","volume":"5","author":"Cooper","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.conctc.2018.100308_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11096-015-0199-8","article-title":"Clinical medication reviews in elderly patients with polypharmacy: a cross-sectional study on drug-related problems in The Netherlands","volume":"38","author":"Chau","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.conctc.2018.100308_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/0002512-200926020-00004","article-title":"Pharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trial","volume":"26","author":"Vinks","year":"2009","journal-title":"Drugs Aging"},{"year":"2010","series-title":"Multidisciplinaire Richtlijn Ziekte Van Parkinson","author":"Bloem","key":"10.1016\/j.conctc.2018.100308_bib42"},{"issue":"3","key":"10.1016\/j.conctc.2018.100308_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.conctc.2018.100308_bib44","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s12445-013-0215-y","article-title":"Multidisciplinaire richtlijn Polyfarmacie bij ouderen","volume":"56","author":"Verduijn","year":"2013","journal-title":"Huisarts Wet."},{"issue":"3","key":"10.1016\/j.conctc.2018.100308_bib45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/0897190014550003","article-title":"Concordance of pharmacist assessment of medication nonadherence with a self-report medication adherence scale","volume":"29","author":"Kelly","year":"2016","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.conctc.2018.100308_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1471-2458-10-133","article-title":"Effect of medication review and cognitive behaviour treatment by community pharmacists of patients discharged from the hospital on drug related problems and compliance: design of a randomized controlled trial","volume":"10","author":"Ahmad","year":"2010","journal-title":"BMC Publ. Health"},{"key":"10.1016\/j.conctc.2018.100308_bib47","doi-asserted-by":"crossref","first-page":"21122","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The validity of the Rx-risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification system","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.conctc.2018.100308_bib48","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/WNL.55.6.888","article-title":"Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study","volume":"55","author":"M\u00fcller","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.conctc.2018.100308_bib49","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","article-title":"The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score","volume":"26","author":"Jenkinson","year":"1997","journal-title":"Age Ageing"},{"issue":"2","key":"10.1016\/j.conctc.2018.100308_bib50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/jnnp.72.2.241","article-title":"Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments","volume":"72","author":"Marinus","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.conctc.2018.100308_bib51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/30.4.299","article-title":"Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire","volume":"30","author":"Peto","year":"2001","journal-title":"Age Ageing"},{"issue":"1","key":"10.1016\/j.conctc.2018.100308_bib52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1477-7525-3-83","article-title":"The Academic Medical Center Linear Disability Score (ALDS) item bank: item response theory analysis in a mixed patient population","volume":"3","author":"Holman","year":"2005","journal-title":"Health Qual. Life Outcome"},{"key":"10.1016\/j.conctc.2018.100308_bib53","first-page":"290195","article-title":"The frequency of nonmotor symptoms among advanced Parkinson patients may depend on instrument used for assessment","volume":"2011","author":"Hwynn","year":"2011","journal-title":"Parkinsons Dis."},{"issue":"7","key":"10.1016\/j.conctc.2018.100308_bib54","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mds.20844","article-title":"International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study","volume":"21","author":"Chaudhuri","year":"2006","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.conctc.2018.100308_bib55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/jnnp.69.1.67","article-title":"The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease","volume":"69","author":"Schrag","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.conctc.2018.100308_bib56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann. Med."},{"issue":"4","key":"10.1016\/j.conctc.2018.100308_bib57","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.parkreldis.2012.11.018","article-title":"The PDQ-Carer: development and validation of a summary index score","volume":"19","author":"Morley","year":"2013","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.conctc.2018.100308_bib58","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ageing\/afl055","article-title":"The Parkinson's Disease Questionnaire (PDQ-39): evidence for a method of imputing missing data","volume":"35","author":"Jenkinson","year":"2006","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.conctc.2018.100308_bib59","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/fampra\/cmx007","article-title":"The effectiveness of optimised clinical medication reviews for geriatric patients: opti-Med a cluster randomised controlled trial","volume":"34","author":"Willeboordse","year":"2017","journal-title":"Fam. Pract."},{"key":"10.1016\/j.conctc.2018.100308_bib60","first-page":"D1772","article-title":"Periodical medication review: bigger and better?","volume":"161","author":"van Marum","year":"2017","journal-title":"Ned. Tijdschr. Geneeskd."},{"issue":"3","key":"10.1016\/j.conctc.2018.100308_bib61","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.sapharm.2013.10.004","article-title":"A segmentation analysis for pharmacists' and patients' views of pharmacists' roles","volume":"10","author":"Schommer","year":"2014","journal-title":"Res. Soc. Adm. Pharm."},{"issue":"1","key":"10.1016\/j.conctc.2018.100308_bib62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0000000000000260","article-title":"Effect of pharmacist-led interventions on (non)motor symptoms, medication-related problems, and quality of life in Parkinson disease patients: a pilot study","volume":"41","author":"Stuijt","year":"2018","journal-title":"Clin. Neuropharmacol."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865418301339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865418301339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:01:03Z","timestamp":1762520463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865418301339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":62,"alternative-id":["S2451865418301339"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2018.100308","relation":{},"ISSN":["2451-8654"],"issn-type":[{"type":"print","value":"2451-8654"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of a structured medication review on quality of life in Parkinson's disease: The study protocol","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2018.100308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100308"}}